The New York Times is reporting on a common practice by disability insurance providers to deny coverage to users of Truvada, a medication also known as pre-exposure prophylaxis (PrEP), that prevents H.I.V. infection. Reporter Donald G. McNeil interviewed healthcare providers, H.I.V. awareness advocates and Truvada users about the medication and why its increasingly popular as an effective strategy for preventing infection. As McNeil points out, the insurance strategy appears to contradict policies towards other preventive medications like birth control and HPV vaccines. Click here to read McNeil’s full report in NYT.